Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (-4.03%) As of 08/6/2025 09:55 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. PPBT, LIAN, GTBP, SPRB, VYNE, BCTX, KTTA, SLXN, THAR, and CPHIShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Purple Biotech (PPBT), LianBio (LIAN), GT Biopharma (GTBP), Spruce Biosciences (SPRB), VYNE Therapeutics (VYNE), Briacell Therap (BCTX), Pasithea Therapeutics (KTTA), Silexion Therapeutics (SLXN), Tharimmune (THAR), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Its Competitors Purple Biotech LianBio GT Biopharma Spruce Biosciences VYNE Therapeutics Briacell Therap Pasithea Therapeutics Silexion Therapeutics Tharimmune China Pharma Purple Biotech (NASDAQ:PPBT) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment. Do institutionals and insiders hold more shares of PPBT or ADXS? 9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, PPBT or ADXS? Purple Biotech has higher earnings, but lower revenue than Ayala Pharmaceuticals. Purple Biotech is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPurple BiotechN/AN/A-$7.24M-$2.62-0.82Ayala Pharmaceuticals$3.24M0.44-$48.07M-$7.980.00 Does the media prefer PPBT or ADXS? In the previous week, Purple Biotech had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Purple Biotech and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Purple Biotech's score of -1.50 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Purple Biotech Very Negative Ayala Pharmaceuticals Neutral Which has more volatility and risk, PPBT or ADXS? Purple Biotech has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Do analysts prefer PPBT or ADXS? Purple Biotech currently has a consensus price target of $33.00, suggesting a potential upside of 1,434.88%. Given Purple Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Purple Biotech is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PPBT or ADXS more profitable? Ayala Pharmaceuticals' return on equity of 0.00% beat Purple Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Purple BiotechN/A -17.84% -15.44% Ayala Pharmaceuticals N/A N/A N/A SummaryPurple Biotech beats Ayala Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42M$782.21M$5.57B$9.47BDividend YieldN/A4.84%4.31%4.13%P/E Ratio0.001.3029.3723.99Price / Sales0.4425.47444.1896.63Price / CashN/A19.5635.8458.51Price / Book-0.026.598.085.58Net Income-$48.07M-$4.20M$3.26B$265.35M7 Day PerformanceN/A-3.87%0.45%-0.07%1 Month PerformanceN/A-0.67%4.83%1.76%1 Year PerformanceN/A21.24%30.28%25.39% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-4.0%N/A+66.5%$1.42M$3.24M0.0020Gap DownPPBTPurple Biotech2.3189 of 5 stars$2.30+3.8%$33.00+1,337.9%N/A$5.83MN/A-0.8620News CoverageEarnings ReportLIANLianBioN/A$0.05-2.4%N/A-81.9%$5.73MN/A-0.07110Gap UpGTBPGT Biopharma2.0273 of 5 stars$1.74-2.5%$11.00+534.0%-25.6%$5.67MN/A-0.308Upcoming EarningsSPRBSpruce Biosciences2.4941 of 5 stars$0.13+11.7%$131.25+97,847.8%-99.6%$5.66M$4.91M-0.1420News CoverageNegative NewsUpcoming EarningsGap DownVYNEVYNE Therapeutics2.5366 of 5 stars$0.36-1.4%$6.25+1,636.1%-79.4%$5.48M$500K-0.3630Upcoming EarningsHigh Trading VolumeBCTXBriacell Therap1.875 of 5 stars$0.78+2.6%$32.00+4,029.0%-93.0%$5.25MN/A-0.098Stock SplitKTTAPasithea Therapeutics0.6485 of 5 stars$0.70-2.0%N/A-86.4%$5.18MN/A-0.073Upcoming EarningsSLXNSilexion TherapeuticsN/A$8.89-1.7%$75.00+744.1%N/A$5.15MN/A0.00N/ATHARTharimmune3.4118 of 5 stars$1.22-8.3%$17.00+1,293.4%-56.3%$5.15MN/A-0.152News CoverageUpcoming EarningsGap DownCPHIChina PharmaN/A$1.57-1.9%N/A-90.9%$5.12M$4.30M0.00250 Related Companies and Tools Related Companies Purple Biotech Alternatives LianBio Alternatives GT Biopharma Alternatives Spruce Biosciences Alternatives VYNE Therapeutics Alternatives Briacell Therap Alternatives Pasithea Therapeutics Alternatives Silexion Therapeutics Alternatives Tharimmune Alternatives China Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
